SXTP
60 DEGREES PHARMACEUTICALS, INC.
NASDAQ · Healthcare · Biotechnology · US
$0.83
−3.29%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$0.86
From 52W high−86.21%
Volume39721.00
Market cap$2.91M
P/E (TTM)—
P/S (TTM)2.6x
Div yield—
Key dataOct 19, 2026
Open
$0.86
From 52W high
−86.21%
Volume
39721.00
Market cap
$2.91M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.4x
P/E (TTM)
—
RSI (14)
38.7
MomentumView details →
1D Return
−3.29%
YTD Return
−56.65%
SummaryUpdated Jun 1, 2026
60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) is a specialty pharmaceutical company founded in 2010 and headquartered in Washington, D.C. The company went public in July 2023 and focuses on developing and commercializing therapies for the prevention and treatment of infectious diseases. Since its IPO, the company has experienced significant stock price volatility, declining from over $16 per share in 2023 to around $2 per share currently, reflecting the challenges typical of early-stage biotech companies with limited commercial revenue.
Similar companies
Latest newsMore news →
60 Degrees Pharmaceuticals announced it will conclude enrollment in its randomized clinical study of tafenoquine in hospitalized babesiosis patients, with primary and secondary endpoint results expected in January 2027.14d ago60 Degrees Pharmaceuticals announced that interim analysis results from its clinical study of tafenoquine in severe babesiosis will be released on October 6, 2026, along with a key opinion leader investor webinar featuring Dr. Peter Krause and Dr. Edouard Vannier.19d ago60 Degrees Pharmaceuticals, Inc. signed a securities purchase agreement for a private placement offering of common stock, pre-funded warrants, and Series A and Series B common warrants, with gross proceeds of approximately $1.0 million.78d ago